HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

An important goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that elicit effective antiviral humoral immunity. One novel approach comprises priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on virus-like particles....

Full description

Saved in:
Bibliographic Details
Published in:J Virol
Main Authors: Shen, Xiaoying, Basu, Rahul, Sawant, Sheetal, Beaumont, David, Kwa, Sue Fen, LaBranche, Celia, Seaton, Kelly E., Yates, Nicole L., Montefiori, David C., Ferrari, Guido, Wyatt, Linda S., Moss, Bernard, Alam, S. Munir, Haynes, Barton F., Tomaras, Georgia D., Robinson, Harriet L.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2017
Subjects:
Vaccines and Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709589/
https://ncbi.nlm.nih.gov/pubmed/29021394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01077-17
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items